We are a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. Our novel proprietary technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12 months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical outcomes. Our lead product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib, a potent inhibitor of neovascular growth and permeability, which are leading causes of retinal disease. We are developing GB-102 as a once-every-six months intravitreal injection for the treatment of wet age-related macular degeneration, or wet AMD, and diabetic macular edema, or DME.
We are also using our proprietary technologies to develop GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy, or DR, as well as GB-401, an intravitreally injectable depot formulation of a beta-adrenergic blocking agent prodrug with a dosing regimen of once every six months or longer for the treatment of primary open-angle glaucoma, or POAG.
|Address||275 Shoreline Drive, Suite 450 Redwood City, CA 94065|
|Phone Number||(650) 487-2800|
|View Prospectus:||Graybug Vision|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-43.6 mil (last 12 months)|
|Price range||$16.00 - $16.00|
|Est. $ Volume||$90.0 mil|
|Manager / Joint Managers||SVB Leerink/ Piper Sandler|
|CO-Managers||Needham & Co./ Wedbush PacGrow|
|Expected To Trade:||9/25/2020|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|